Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA-approved product, is a targeted immunotherapy for the treatment of cutaneous T-cell lymphoma. The company's late-stage pipeline includes Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections; Halo-Lido, a corticosteroid-lidocaine topical formulation to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; and NoveCite, a mesenchymal stem cell therapy for the treatment of ARDS. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.
Frequently asked questions
What sector does Citius Pharmaceuticals, Inc (CTXR) operate in?
Citius Pharmaceuticals, Inc belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Citius Pharmaceuticals, Inc (CTXR) current stock price?
As of the latest data, Citius Pharmaceuticals, Inc stock price is $0.58, with a previous close of $0.76. Citius Pharmaceuticals, Inc lost -$0.18 in the last trading session, representing a -23.76% loss.
What is Citius Pharmaceuticals, Inc (CTXR) current market capitalization?
Citius Pharmaceuticals, Inc market cap is approximately 15.82 million.
What is Citius Pharmaceuticals, Inc (CTXR) Earnings Per Share (EPS)?
The trailing EPS is -$2.14, and the forward EPS is -$0.81.
What is Citius Pharmaceuticals, Inc (CTXR) EBITDA?
Citius Pharmaceuticals, Inc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -30.43 million.
Does Citius Pharmaceuticals, Inc (CTXR) pay dividends?
No. Citius Pharmaceuticals, Inc does not pay a dividend.
When is Citius Pharmaceuticals, Inc (CTXR) next earnings report?
Citius Pharmaceuticals, Inc is expected to release its next earnings report on June 30, 2026.
What is Citius Pharmaceuticals, Inc (CTXR) beta (volatility) score?
Citius Pharmaceuticals, Inc has a beta of 0.994, meaning its volatility is roughly in line with the market.
